ClinicalTrials.gg
RecruitingNCT06140537Updated May 29, 2025

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

A Phase 4 interventional study of Dapagliflozin 10mg Tab and Placebo in Kidney Transplant; Complications, Vascular Diseases and Diabetes, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by University of Colorado, Denver · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 243 studies in Vascular Diseases with a site in United States — 47 open to participants now, 65 under way, 3 of them phase 3. Vascular Diseases · United States.

Planned enrollment
86th of 175
80 · median 76
Started
2024
with 12 others
Phase 4
16 of 243
5 open now
Primary completion
2028-10
later than 43 of 63 live
Registered
205th of 243
by date

Among the 243 studies in Vascular Diseases with a site in United States, this one is the 86th largest by planned enrollment of the 175 interventional ones that give a count, is one of 13 that started in 2024, is one of 16 in phase 4, reaches primary completion later than 43 of the 63 other live ones, and was the 205th registered.

Vascular Diseases

694 studies on the registry are indexed under Vascular Diseases; 127 are open to participants now.

Browse Vascular Diseases studies →

Open to participants now

47 of the 243 studies in Vascular Diseases with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 95 Vascular Diseases studies recruiting now, 59 (62%) set no upper age limit and 13 (14%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 243 studies in Vascular Diseases with a site in United States, or all of them as a file.
02

Study summary

Long-term allograft function in kidney transplant recipients (KTRs) remain suboptimal, and graft failure causes significant morbidity and mortality, with cardiovascular disease being the leading cause of death in KTRs and the most common cause of death with a functioning graft. Sodium-glucose cotransporter 2 (SGLT2) inhibitors safely lower cardiovascular and kidney disease risk in the non-transplant population, yet data in KTRs are lacking. This clinical trial seeks to establish the efficacy and safety of dapagliflozin, a SGLT2 inhibitor, for improving cardiovascular and kidney graft function in adult KTRs with type 2 diabetes and post-transplant diabetes, and to leverage innovate translational methods to define the underlying mechanisms of action.

03

Conditions studied

  • Kidney Transplant; Complications
  • Vascular Diseases
  • Diabetes
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • Kidney transplant received 1 year prior to randomization
  • estimated 30-90 ml/min/1.73m2
  • Urine albumin to creatinine ratio (ACR) 30-5000 mg/g
  • Pre-existing type 2 diabetes or post-transplant diabetes mellitus
  • Blood pressure \<130/80 mm Hg prior to randomization
  • Able to provide
  • Stable for at least 3 months prior to baseline consisting of tacrolimus, mycophenolate mofetil/mycophenolic acid and prednisone
  • Stable anti-hypertensive regimen for at least 1month prior to baseline
  • Stable diabetes management for at least 3 months prior to baseline
  • Stable angiotensin converting enzyme inhibitor/angiotensin receptor blocker use for at least 3 months prior to baseline (if applicable)
  • Glucagon-like peptide-1 receptor agonist (GLP-1RA) for at least 3 months prior to baseline (if applicable)

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Anticipated \<1 year
  • Uncontrolled hypertension
  • >9%
  • >40 kg/m2
  • Class 3 or 4 heart failure symptoms, an EF ≤30%, or hospitalization for heart failure in the past 3 months
  • Pregnancy, plans to become pregnant, or breastfeeding
  • Current use of sodium glucose cotransporter-2 (SGLT2) inhibitors
  • Current urinary or urogenital infection
  • Use of anticoagulants ( to kidney )
  • Magnetic resonance imaging (MRI) contraindications
  • History of lower-limb amputation irrespective of etiology
  • Known to dapagliflozin
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin

    Participants will receive dapagliflozin 10mg daily

    Drug: Dapagliflozin 10mg Tab

  • Placebo comparator
    Placebo

    Participants will receive one placebo tablet daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Albuminuria

    Measured by urine albumin to creatinine ratio

    Time frame: Change from baseline to 12 months

Secondary outcomes

  1. Kidney fibrosis

    Measured by Magnetic Resonance Imaging (MRI) and kidney biopsy tissue

    Time frame: Change from baseline to 12 months

  2. Kidney oxygenation

    Measured by MRI

    Time frame: Change from baseline to 12 months

  3. Arterial stiffness

    Measured by aortic pulse wave velocity

    Time frame: Change from baseline to 12 months

  4. Left ventricular mass

    measured by cardiac MRI

    Time frame: Change from baseline to 12 months

  5. estimated glomerular filtration rate

    estimated by CKD epi equation

    Time frame: Change from baseline to 12 months

  6. Kidney morphometry, metabolomics from paired kidney biopsies

    measured by single cell RNA sequencing from paired kidney biopsies

    Time frame: Change from baseline to 12 months

  7. safety and tolerability

    assessed on basis of adverse events

    Time frame: baseline, 6 and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use. The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.

Supporting information: Study protocol, Statistical analysis plan

Time frame: At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use. The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Oct 2028, 56 months after the start.

Of 16 phase 4 interventional studies under Vascular Diseases, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 84. This study's planned 56 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 20, 2023
StartActual
Feb 1, 2024
Primary completionEst.
Oct 31, 2028
CompletionEst.
Dec 31, 2028
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06140537
Responsible party
Sponsor
First posted
Nov 20, 2023
Start date
Feb 1, 2024
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 29, 2025

Study contacts

Jessica Kendrick
Contact
Jessica.Kendrick@cuanschutz.edu
3037244837
Petter Bjornstad
Contact
petter.bjornstad@cuanschutz.edu

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion